CBRE Group, Inc. CBRE recently announced its plans to purchase all the issued and to-be-issued shares of Telford Homes Plc. Telford is a well-known developer of multifamily residential properties in London, with a development in-process portfolio (total project cost) worth $1.66 billion.
Per the terms of the deal, Telford shareholders will receive $4.41 per share in cash, thus, valuing Telford at $336.9 million. CBRE has announced a bridge acquisition facility to confirm the availability of financial resources, however, it intends to fulfill the offer through a combination of cash on hand and availability under its revolving credit facility.
The acquisition will enable CBRE to expand its highly successful Trammell Crow Company real estate development business in the U.K. and Europe. In fact, Trammell Crow Company has achieved impressive earnings growth over the past five years, as well as produced robust returns for its capital partners.
The acquisition is expected to conclude in third-quarter 2019, upon which, Telford will operate as part of the Trammell Crow Company. Its financial results will be reported in CBRE’s Real Estate Investments business segment.
Importantly, the transaction is subject to customary regulatory approvals. While Telford’s board has committed to vote in favor of the proposal, the deal requires at least 75% of the company’s shareholders to vote in the deal’s favor.
Notably, Telford is focused on development of middle-market build-to-rent properties in London. Greater affordability relative to for-sale housing properties and limited supply is shifting inclination from home ownership to renting. This is fueling the rental housing market’s growth in Britain, which is in its nascent stage as compared to the renter-housing market in the United States that has flourished over the decades.
In fact, for the 12-month period ended Mar 31, 2019, Telford generated revenues of nearly $446 million and pre-tax profit of $50 million.
Shares of this Zacks Rank #1 (Strong Buy) company have gained 4%, as compared with the industry’s rally of 3%, over the past three months. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Key Picks
FirstService Corporation FSV flaunts a Zacks Rank of 1, currently. The Zacks Consensus Estimate for the company’s 2019 EPS moved up nearly 5% to $2.96, over the last 30 days.
Cushman & Wakefield CWK carries a Zacks Rank of 2 (Buy), at present. The company’s Zacks Consensus Estimate for the ongoing year’s EPS have been revised marginally north to $1.66, in 30 days’ time.
PennyMac Mortgage Investment Trust PMT currently carries a Zacks Rank of 2. The company has seen the Zacks Consensus Estimate for the current-year EPS being revised around 14% upward over the past two months to $2.06.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
FirstService Corporation (FSV) : Free Stock Analysis Report
PennyMac Mortgage Investment Trust (PMT) : Free Stock Analysis Report
Cushman & Wakefield PLC (CWK) : Free Stock Analysis Report
CBRE Group, Inc. (CBRE) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research